191 related articles for article (PubMed ID: 37819629)
1. Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models.
Liu G; Lipari P; Mollin A; Jung S; Teplova I; Li W; Ying L; More V; Lennox W; Yeh S; McGann E; Moon YC; Rice C; Huarte E; Gruszka B; Ray B; Goodwin E; Buckendahl P; Yurkow E; Braughton B; Narasimhan J; Welch E; Voronin G; Weetall M
Hum Mol Genet; 2024 Jan; 33(3):211-223. PubMed ID: 37819629
[TBL] [Abstract][Full Text] [Related]
2. Corticosteroids for the treatment of Duchenne muscular dystrophy.
Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY
Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
[TBL] [Abstract][Full Text] [Related]
4. Considering the Promise of Vamorolone for Treating Duchenne Muscular Dystrophy.
Grounds MD; Lloyd EM
J Neuromuscul Dis; 2023; 10(6):1013-1030. PubMed ID: 37927274
[TBL] [Abstract][Full Text] [Related]
5. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.
Biggar WD; Skalsky A; McDonald CM
J Neuromuscul Dis; 2022; 9(4):463-476. PubMed ID: 35723111
[TBL] [Abstract][Full Text] [Related]
6. Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone.
Fiorillo AA; Tully CB; Damsker JM; Nagaraju K; Hoffman EP; Heier CR
Physiol Genomics; 2018 Sep; 50(9):735-745. PubMed ID: 29883261
[TBL] [Abstract][Full Text] [Related]
7. Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy.
Shieh PB; Elfring G; Trifillis P; Santos C; Peltz SW; Parsons JA; Apkon S; Darras BT; Campbell C; McDonald CM; ; ; ;
J Comp Eff Res; 2021 Dec; 10(18):1337-1347. PubMed ID: 34693725
[No Abstract] [Full Text] [Related]
8. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial.
Shieh PB; Mcintosh J; Jin F; Souza M; Elfring G; Narayanan S; Trifillis P; Peltz SW; Mcdonald CM; Darras BT;
Muscle Nerve; 2018 Nov; 58(5):639-645. PubMed ID: 30028519
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy.
Mavroudis PD; van den Anker J; Conklin LS; Damsker JM; Hoffman EP; Nagaraju K; Clemens PR; Jusko WJ
J Clin Pharmacol; 2019 Jul; 59(7):979-988. PubMed ID: 30742306
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
[TBL] [Abstract][Full Text] [Related]
11. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
Heier CR; Yu Q; Fiorillo AA; Tully CB; Tucker A; Mazala DA; Uaesoontrachoon K; Srinivassane S; Damsker JM; Hoffman EP; Nagaraju K; Spurney CF
Life Sci Alliance; 2019 Feb; 2(1):. PubMed ID: 30745312
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial.
Dang UJ; Damsker JM; Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans NM; Haberlová J; Straub V; Mengle-Gaw L; Schwartz BD; Harper A; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster RI; Mcmillan HJ; Kuntz N; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez JJ; Nascimento-Osorio A; Niks EH; De Groot IJM; Katsalouli M; Van Den Anker JN; Ward LM; Leinonen M; D'Alessandro AL; Hoffman EP
Neurology; 2024 Mar; 102(5):e208112. PubMed ID: 38335499
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
[TBL] [Abstract][Full Text] [Related]
14. Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice.
Ziemba M; Barkhouse M; Uaesoontrachoon K; Giri M; Hathout Y; Dang UJ; Gordish-Dressman H; Nagaraju K; Hoffman EP
PLoS One; 2021; 16(2):e0246507. PubMed ID: 33617542
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Deflazacort Treatment on the Functioning of Skeletal Muscle Mitochondria in Duchenne Muscular Dystrophy.
Dubinin MV; Talanov EY; Tenkov KS; Starinets VS; Belosludtseva NV; Belosludtsev KN
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228255
[TBL] [Abstract][Full Text] [Related]
17. Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy.
Lit L; Sharp FR; Apperson M; Liu DZ; Walker WL; Liao I; Xu H; Ander BP; Wong B
Pharmacogenomics J; 2009 Dec; 9(6):411-8. PubMed ID: 19488064
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP
JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925
[TBL] [Abstract][Full Text] [Related]
19. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
McDonald CM; Sajeev G; Yao Z; McDonnell E; Elfring G; Souza M; Peltz SW; Darras BT; Shieh PB; Cox DA; Landry J; Signorovitch J;
Muscle Nerve; 2020 Jan; 61(1):26-35. PubMed ID: 31599456
[TBL] [Abstract][Full Text] [Related]
20. Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy.
Anderson JE; Weber M; Vargas C
Cell Transplant; 2000; 9(4):551-64. PubMed ID: 11038071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]